4.7 Article

Anosognosia predicts default mode network hypometabolism and clinical progression to dementia

Journal

NEUROLOGY
Volume 90, Issue 11, Pages E932-501

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000005120

Keywords

-

Funding

  1. Canadian Institutes of Health Research [MOP-11-51-31]
  2. Alan Tiffin Foundation
  3. Alzheimer's Association [NIRG-12-92090, NIRP-12-259245]
  4. Fonds de Recherche du Quebec-Sante
  5. Centre for Studies on Prevention of AD (StoP-AD Centre)
  6. ADNI (NIH grant) [U01 AG024904]
  7. DOD ADNI (Department of Defence) [W81XWH-12-2-0012]
  8. National Institute on Aging
  9. National Institute of Biomedical Imaging and Bioengineering
  10. AbbVie
  11. Alzheimer's Association
  12. Alzheimer's Drug Discovery Foundation
  13. Araclon Biotech
  14. BioClinica, Inc.
  15. Biogen
  16. Bristol-Myers Squibb
  17. CereSpir, Inc.
  18. Eisai Inc.
  19. Elan Pharmaceuticals, Inc.
  20. Eli Lilly and Company
  21. EuroImmun
  22. F. Hoffmann-La Roche Ltd.
  23. Genentech, Inc.
  24. Fujirebio
  25. GE Healthcare
  26. IXICO Ltd.
  27. Janssen Alzheimer Immunotherapy Research & Development, LLC
  28. Johnson & Johnson Pharmaceutical Research & Development LLC
  29. Lumosity
  30. Lundbeck
  31. Merck Co., Inc.
  32. Meso Scale Diagnostics, LLC
  33. NeuroRx Research
  34. Neurotrack Technologies
  35. Novartis Pharmaceuticals Corporation
  36. Pfizer Inc.
  37. Piramal Imaging
  38. Servier
  39. Takeda Pharmaceutical Company
  40. Transition Therapeutics
  41. Canadian Institutes of Health Research

Ask authors/readers for more resources

Objective To identify the pathophysiologic mechanisms and clinical significance of anosognosia for cognitive decline in mild cognitive impairment. Methods We stratified 468 patients with amnestic mild cognitive impairment into intact and impaired awareness groups, determined by the discrepancy between the patient and the informant score on the Everyday Cognition questionnaire. Voxel-based linear regression models evaluated the associations between self-awareness status and baseline beta-amyloid load, measured by [F-18] florbetapir, and the relationships between awareness status and regional brain glucose metabolism measured by [F-18] fluorodeoxyglucose at baseline and at 24-month follow-up. Multivariate logistic regression tested the association of awareness status with conversion from amnestic mild cognitive impairment to dementia. Results We found that participants with impaired awareness had lower [F-18] fluorodeoxyglucose uptake and increased [F-18] florbetapir uptake in the posterior cingulate cortex at baseline. In addition, impaired awareness in mild cognitive impairment predicted [F-18] fluorodeoxyglucose hypometabolism in the posterior cingulate cortex, left basal forebrain, bilateral medial temporal lobes, and right lateral temporal lobe over 24 months. Furthermore, participants with impaired awareness had a nearly 3-fold increase in likelihood of conversion to dementia within a 2-year time frame. Conclusions Our results suggest that anosognosia is linked to Alzheimer disease pathophysiology in vulnerable structures, and predicts subsequent hypometabolism in the default mode network, accompanied by an increased risk of progression to dementia. This highlights the importance of assessing awareness of cognitive decline in the clinical evaluation and management of individuals with amnestic mild cognitive impairment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available